OncoEthix GmbH
Defining the clinical potential of promising oncology drug candidates
Founded in 2009, OncoEthix is a Swiss-based privately held biotechnology company aiming to develop a small portfolio of oncology drug candidates. The Company’s lead product, OTX015, is an investigational orally administered synthetic small molecule targeted to BET bromodomain proteins 2/3/4. OTX015 was in-licensed from Mitsubishi Tanabe Pharma Corporation in March 2012 following completion of Phase I clinical studies in healthy volunteers.
OncoEthix has raised a total of US$30 million in venture capital to date: investors include Index Ventures, SV Life Sciences, Endeavour Vision and Edmond de Rothschild Investment Partners.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
19.12.2014
Merck Acquires OncoEthix (startupticker.ch)
08.07.2013
OncoEthix Closes 18 Million CHF Series B Financing (startupticker.ch)
20.03.2013
OncoEthiX drug against blood cancer tested in patients (startupticker.ch)
18.06.2012
OncoEthix In-Licenses anticancer compound (startupticker.ch)
No milestones
No Jobs
No videos and documents
No Awards
OncoEthix GmbH
Defining the clinical potential of promising oncology drug candidates
Website:
www.oncoethix.ch
Merck
Headquarter:
Lucerne
Foundation Date:
March 2007
Technology:
- Biotech
Sectors:
- Cancer
- Drug discovery